Trial Profile
A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs CRS 207 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 29 Aug 2023 Status changed from active, no longer recruiting to completed.
- 14 Aug 2023 Planned End Date changed from 3 Aug 2023 to 31 Oct 2023.
- 16 Jun 2023 Timeline for primary end-point changed from 4 years to 18 months and upper age limit of 100 years removed from inclusion criteria.